US4871764A - 12-Halogenated forskolin derivatives - Google Patents

12-Halogenated forskolin derivatives Download PDF

Info

Publication number
US4871764A
US4871764A US06/932,553 US93255386A US4871764A US 4871764 A US4871764 A US 4871764A US 93255386 A US93255386 A US 93255386A US 4871764 A US4871764 A US 4871764A
Authority
US
United States
Prior art keywords
compound
sub
mmole
ether
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/932,553
Other languages
English (en)
Inventor
Gregory M. Shutske
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Assigned to HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED reassignment HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: SHUTSKE, GREGORY M.
Priority to US06/932,553 priority Critical patent/US4871764A/en
Priority to EP87116919A priority patent/EP0268256A3/en
Priority to IE873119A priority patent/IE873119L/xx
Priority to KR870013004A priority patent/KR880006223A/ko
Priority to JP62290788A priority patent/JPS63135379A/ja
Priority to DK607787A priority patent/DK607787A/da
Priority to PT86176A priority patent/PT86176B/pt
Priority to ZA878659A priority patent/ZA878659B/xx
Priority to HU875134A priority patent/HU203886B/hu
Priority to US07/390,126 priority patent/US4978678A/en
Publication of US4871764A publication Critical patent/US4871764A/en
Application granted granted Critical
Priority to US07/522,754 priority patent/US5023344A/en
Priority to US07/673,449 priority patent/US5070209A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans

Definitions

  • the present invention relates to 12-halogenated forskolin derivatives of Formula 1 ##STR1## wherein X is F, Cl, Br and I; R is hydrogen, ##STR2## wherein R 1 is hydrogen or lower alkyl, ##STR3## where R 2 , R 3 are the same or different and are H or lower alkyl; the optical and geometric isomers thereof, which are useful for reducing intraocular pressure, alone or in combination with inert adjuvants.
  • the present invention also relates to compounds of the formula 2, ##STR4## wherein X is as previously defined and Z is either ##STR5## where R 4 , R 5 are the same or different and are hydrogen or lower alkyl; or the optical and geometric isomers thereof, which are useful as intermediates for the preparation of the 12-halogenated forskolin derivatives of the present invention.
  • alkyl refers to a straight or branched chain hydrocarbon radical containing no unsaturation, such as methyl, ethyl, 1-propyl, 2-propyl, 2-methylpropyl, 1-pentyl, 3-hexyl, and the like.
  • alkanoyl refers to a monovalent substituent which consists of an alkyl group linked through a carbonyl group having its free valence bond from the carbon of the carbonyl group ##STR6## Examples of alkanoyl groups are formyl, acetyl, propionyl, 2,2-dimethylacetyl, hexanoyl, and the like.
  • lower as applied to any of the aforementioned groups refers to an alkyl group having a carbon skeleton containing up to and including 6 carbon atoms.
  • the substituents thereon may also contain chiral centers contributing to the optical properties of the compounds of the present invention and providing a means for the resolution thereof by conventional methods, for example, by the use of optically active acids.
  • a wavy line ( ⁇ ) connecting a group to a chiral center indicates that the stereochemistry of the center is unknown, i.e. the group may exist in any of the possible orientations.
  • the present invention comprehends all optical isomers and racemic forms of the compounds of the present invention, where such compounds have chiral centers in addition to those of the labdane nucleus.
  • novel 12-halogenated forskolin derivatives of the present invention are synthesized by the processes illustrated in the Reaction Schemes A and B, wherein the groups R, R 1 through R 5 are as previously defined.
  • R 9 and R 10 are independently lower alkyl, or R 8 and R 9 taken together with the nitrogen atom to which they are attached form a group of the formula ##STR8## where X is CHR 11 wherein R 11 is hydrogen, lower alkyl or a group of the formula OR 12 where R 12 is hydrogen, lower alkyl or a group of the formula COR 13 wherein R 13 is lower alkyl and m is 0 or 1.
  • the condensation is preferably performed in the absence of an added solvent, excess formamide dialkylacetal serving both as the reactant and solvent.
  • a dipolar aprotic solvent such as dimethylformamide, dimethylacetamide, hexamethylphosphoramide or dimethylsulfoxide may be employed, however, as the reaction medium.
  • the temperature at which the condensation is conducted is not critical. A condensation temperature within the range of about 25° to about 100° C. is generally employed to assure a reasonable rate of reaction. A temperature of about 45° to about 65° C. is preferred.
  • a 7 ⁇ -alkanoyloxy-6 ⁇ -hydroxylabdane 4 is hydrolyzed to the 6 ⁇ , 7 ⁇ -dihydroxylabdane 5.
  • the hydrolysis is carried out in an aqueous alkanol such as aqueous methanol, ethanol, 1- or 2-propanol or t-butanol, aqueous methanol being preferred, containing an alkali carbonate such as lithium, sodium or potassium carbonte, potassium carbonate being preferred, at a hydrolysis temperature within the range of about 10° to about 75° C., a hydrolysis temperature of about 25° C. being preferred.
  • a 6 ⁇ ,7 ⁇ -dihydroxylabdane of formula 5 is treated with a compound of formula 12.
  • Hal is bromo or chloro, preferably chloro, in the presence of an organic base such as trimethyl- or triethylamine, pyridine, lutidine or collidine at a reduced temperature within the range of about -24° to about 25° C.
  • the preferred organic base is pyridine and the preferred reaction temperature is about 0° C.
  • labdane 6 can be prepared by treating the 6 ⁇ ,7 ⁇ -dihydroxylabdane 5 with a compound of the formula ##STR10## where R 14 is imidazole, ##STR11## in the presence of an organic base such as trimethyl or triethylamine, diisopropyl-ethylamine, etc., at a temperature ranging from 25° to 150 ° C. for a time period of 30 to 120 minutes.
  • an organic base such as trimethyl or triethylamine, diisopropyl-ethylamine, etc.
  • Labdane 6 is treated with a silyl halide of the formula 13 ##STR12## where R 15 , R 16 , R 17 are independently lower alkyl and Hal is a halogen, preferably Cl, in the presence of a base such as potassium hydride, lithium diisopropylamide or, preferably, lithium bis[trimethylsilyl]amide to form labdane 7.
  • a base such as potassium hydride, lithium diisopropylamide or, preferably, lithium bis[trimethylsilyl]amide
  • this reaction is carried out in the presence of an aprotic solvent, e.g. tetrahydrofuran, diethyl ether, dimethoxy ethane, tolune, etc., at a temperature of -25° to 25° C. for a period of time of from 1 to 3 hours.
  • labdane 7 is reacted in a conventional manner with a N-halosuccinimide such as N-bromo-, N-chloro-, N-iodosuccinimide, etc., or other standard suitable halogenating agents such as N-halophthalimide or N-halocarprolactam, under the influence of flouride ion.
  • a N-halosuccinimide such as N-bromo-, N-chloro-, N-iodosuccinimide, etc.
  • suitable halogenating agents such as N-halophthalimide or N-halocarprolactam
  • Tetramethylammonium fluoride, tetraethylammonium flouride, benzyltrimethylammonium fluoride and potassium fluoride dicyclohexyl-18-crown-6 are suitable sources of fluoride ion, with tetra-n-butylammonium fluoride being preferred.
  • the reaction is carried out in a polar aprotic solvent, e.g. diethyl ether, tetrahydrofuran, or dimethoxy ethane at a temperature of -65° to 0° C. for a time period of 5 to 60 minutes to form labdane 8, where Hal is a halogen (cl, Br, or I).
  • a polar aprotic solvent e.g. diethyl ether, tetrahydrofuran, or dimethoxy ethane
  • compound 8 is removed by hydrolyzing compound 8 by conventional means.
  • compound 8 is treated with a basic material, e.g. K 2 CO 3 , Li 2 CO 3 , Na 2 CO 3 , etc., in the presence of water and a miscible organic solvent, e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc., at a temperature ranging from 25° to 60° C. for a time period of 1 to 8 hours in order to form compound 9.
  • a basic material e.g. K 2 CO 3 , Li 2 CO 3 , Na 2 CO 3 , etc.
  • a miscible organic solvent e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc.
  • Compound 9 is then subjected to hydrolysis under acidic conditions to form 12-halogenated desacetyl forskolin of the invention of the formula 10.
  • this hydrolysis is carried out in the presence of an organic acid e.g. acetic acid, citric acid, oxalic acid, etc., in water and a miscible organic solvent, e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc. at temperature of 0° to 60° C. for a time period of 1 to 36 hours to obtain compount 10.
  • an organic acid e.g. acetic acid, citric acid, oxalic acid, etc.
  • a miscible organic solvent e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc.
  • reaction Scheme B a dicarbonate labdane of the formula 14 is selected.
  • Such labdanes are known in the art or can be synthesized utilizing conventional techniques. In this regard, reference is made to S.V. Bhat et. al., J. Chemical Society 1982, 767.
  • Labdane 14 is then reacted with the silyl halide 13, in the same manner previously described for reaction of compound 6, to form labdane 15 having a silyl ether group where R 15 , R 16 , and R 17 are as previously defined.
  • halogen group at the 12-position of labdane 15 is carried out in the same manner as previously described for the formation of compound 8 from compound 7 except that the halogen group is restricted to F and Cl, to form labdane 16, where Hal is F or Cl.
  • the resulting dicarbonate 16 is removed by subjecting labdane 16 to basic hydrolysis. Typically this is carried out, as previously described, with an inorganic base, e.g. K 2 CO 3 , Li 2 CO 3 , Na 2 C 3 , etc., in the presence of water and a miscible solvent, e.g. methanol, ethanol, dioxane, etc., at a temperature ranging from 25° to 60° C. for a time period of 1 to 8 hours in order to form compound 10 where Hal is F or Cl.
  • an inorganic base e.g. K 2 CO 3 , Li 2 CO 3 , Na 2 C 3 , etc.
  • a miscible solvent e.g. methanol, ethanol, dioxane, etc.
  • the dicarbonate can be removed in two steps by subjecting labdane 16 to mild basic hydrolysis. Typically this is carried out with an inorganic base, e.g. NaHCO 3 or KHCO 3 in the presence of water and a miscible solvent e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc. at a temperature ranging from 10° to 35° C. for a time period of 6-24 hours in order to form compound 17 where Hal is F or Cl. Labdane 10 can then be obtained from 17 by the conditions described above.
  • an inorganic base e.g. NaHCO 3 or KHCO 3
  • a miscible solvent e.g. methanol, ethanol, dioxane, tetrahydrofuran, etc.
  • compound 10 is reacted under standard acylating conditions.
  • compound 10 is reacted with an acylating agent, e.g. anhydrides, (R 1 C) 2 ), or acid halides, ##STR14## where Hal is a halogen such as Cl, Br, etc., in the presence of a basic solvent such as pyridine, collidine, lutidine, triethylamine etc., at a temperature of 0° to 30° C. for a time period ranging from 1 to 24 hours.
  • an acylating agent e.g. anhydrides, (R 1 C) 2
  • acid halides e.g. anhydrides, (R 1 C) 2 )
  • Hal is a halogen such as Cl, Br, etc.
  • a basic solvent such as pyridine, collidine, lutidine, triethylamine etc.
  • compound 10 is reacted with tetrahydrofuroic acid, ##STR16## in the presence of 1,3-dicyclohexylcarbodiimide and 4-dimethylaminopyridine in an inert solvent such as methylene choloride, chloroform benzene or toluene at a temperature of 0° to 30° C. for a time period of 1 to 24 hours.
  • an inert solvent such as methylene choloride, chloroform benzene or toluene
  • compound 10 is reacted with potassium (2,2-dimethyl-1,3-dioxolano-4yl)oate in the presence of 1,3-dicyclohexylcarbodiimide and 4-dimethylaminopyridine hydrochloride in an inert solvent such as methylene chloride, chloroform, benzene or toluene of a temperature of 0° to 30° C. for a time period of 1 to 24 hours.
  • the resulting intermediate is then subjected to hydrolysis under acidic conditions, typically in the presence of an organic acid e.g. acetic acid, citric acid, oxalic acid, etc. in water and a miscible organic solvent e.g., methanol, ethanol, dioxane, tetrahydrofuran, etc. at a temperature of 0° to 60° for a time period of 1 to 72 hours.
  • organic acid e.g. acetic acid, citric acid, oxalic acid, etc
  • compound 10 is reacted with an isocyanate of the formula R 2 N ⁇ C ⁇ 0 or a carbamoyl chloride of the formula ##STR19## in the presence of an organic base such as lithium diisopropylamide or, preferably, lithium bis[trimethylsilyl]amide in a polar aprotic solvent, e.g. tetrahydrofuran, diethyl ether, dimethoxyethane, etc. at a temperature of 0° to 100° C. for a time period of 1 to 24 hours.
  • an organic base such as lithium diisopropylamide or, preferably, lithium bis[trimethylsilyl]amide
  • a polar aprotic solvent e.g. tetrahydrofuran, diethyl ether, dimethoxyethane, etc.
  • labdane starting materials for the processes of the present invention i.e., labdanes of formula 3 and 14 wherein R 6 is hydrogen or acyl, as described in U.S. Pat. No. 4,134,986, issued Jan. 16, 1979 to B.S. Bajwa, et. al. or may be prepared from compounds disclosed therein by conventional processes.
  • the labdanes of the present invention are useful in the treatment of elevated intraocular pressure by virtue of their ability to reduce intraocular pressure as determined by the method described by J. Caprioli, et al., Invest. Ophthalmol. Vis. Sci., 25, 268 (1984). The results of the determination expressed as percent decrease of outflow pressure is presented in the Table.
  • Intraocular pressure reduction is achieved when the present labdanes are administered to a subject requiring treatment as an effective topical dose of a 0.01 to 3.0% solution or suspension.
  • a particularly effective amount is about 3 drops of a 1% preparation per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judement of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only and that they do not, to any extent, limit the scope or practice of the invention.
  • Effective amounts of the compounds of the present invention may be administered to a subject by any one of various methods, for examply, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, in some cases intravenously in the form of sterile solutions, or suspensions, and topically in the form of solutions, suspension or ointments, and by aerosol spray.
  • Effective quantities of the compounds of the invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the aforesaid compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of active compound in such composition is such that a suitable dosage will be obtained.
  • Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 0.3-30 milligrams of the active compound.
  • the tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as microcrystalline cellulose, gum tragancanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, corn starch and the like; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added.
  • a binder such as microcrystalline cellulose, gum tragancanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, corn starch and the like
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or saccharin or a flavoring agent such as pepper
  • dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
  • tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
  • the active compounds of the invention may be incorporated into a solution, suspension, ointment or cream. These preparations should contain at least 0.01% of active compound, but may be varied between 0.5 and about 5% of the weight thereof. The amount of active compounds in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10 milligrams of active compound.
  • the solutions or suspensions for topical or parenteral administration may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetra-acetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parenteral preparation can be enclosed in ampules or disposable syringes; the topical preparation may be enclosed in multiple dose vials or dropping bottles, made of glass or plastic.
  • Forskolin (100 mg) was dissolved in 1 ml of dimethylformamide dimethylacetal. The mixture was stirred 1 hour at room temperature and overnight at 55° under nitrogen. The mixture was dissolved in ether, washed with water, dried over anhydrous sodium sulfate, filtered and concentrated to an oil. The oil was dissolved in a minimum volume of dichloromethane and chromatographed using 10 g of silica gel (230-400 mesh). Eluant: 8 ⁇ 3 ml of dichloromethane, 8 ⁇ 3 ml of 3% methanol/dichloromethane and 8 ⁇ 3 ml of 5% methanol/dichloromethane. Evaporation of the appropriate fractions followed by drying at 60° C. (1 mm) provided 90 mg (79.1%) of forskolin 1,9-dimethylformamide acetal as an oil.
  • Desacetylforskolin 1,9-dimethylformamide acetal (1,058 g, 2.5 mmole) of Example 4(b) was refluxed in 25 ml of toluene containing 0.50 g of N,N'-carbonyldiimidazole (3.08 mmole) and 0.55 ml of triethylamine (4.0 mmole). After 3 hours, thin layer chromatography (TLC) showed conversion to one main new product. The reaction mixture was evaporated and applied directly to a flash column. Elution with 50% ethyl acetate-hexane gave 0.976 g (87%) of product after combination of the appropriate fractions. Analytically pure desacetylforskolin 6,7-carbonate 1,9-dimethylformamide acetal was obtained by recrystallization from hexane, mp 138°-140° C.
  • the NMR (CDCl 3 ) was consistent with the formation of 12-bromodesacetyl forskolin-6,7-carbonate 1,9-dimethylformamide 11,12-enol-t-butyldimethylsilyl ether.
  • the silyl enol ether was dissolved in 10 ml of dry THF and chilled to -65° C.
  • N-Bromosuccinimide (0.20 g, 1.12 mmole) was then added, followed by 1.1 ml of 1M tetra-n-butylammonium fluoride (1.1 mmole). After 15 minutes the reaction mixture was evaporated and applied directly to a silica gel column.
  • Example 4(f) 12-Bromodesacetyl forskolin (0.2678 g, 0.60 mmole) of Example 4(f) was dissolved in 5 ml CH 2 C1 2 containing 0.120 g (1.02 mmole) of tetrahydrofuroic acid. Dicyclohexylcarbodiimide was added (0.144 g, 0.70 mmole), followed by 4-dimethylaminopyridine (0.085 g, 0.70 mmole) and the reaction mixture was allowed to stir overnight. It was then diluted with ether and filtered through celite.
  • Example 7 The acetonide (0.350 g, 0.608 mmole) of Example 7 was stirred for two days in a solution composed of 5 ml of 80% aqueous acetic acid and 1 ml of methanol. At the end of this time the reaction mixture was distributed between ether and H 2 O, and then the organic phase was washed with NaHCO 3 solution. The residue that remained upon evaporation of the organic phase was purified by flash chromatography (50% ethyl acetate-hexane) to give unreacted starting material and product as a mixture of diastereomers. The recovered starting material was resubjected to the conditions of the hydrolysis for an additional three days and then worked up as before.
  • Example 7 The acetonide (0.350 g, 0.609 mmole) of Example 7 was stirred for two days in a solution composed of 5 ml of 80% aqueous acetic acid and 1 ml of methanol. At the end of this time the reaction mixture was distributed between ether and H 2 O, and then the organic phase was washed with NaHCO 3 solution. The residue that remained upon evaporation of the organic phase was purified by flash chromatography (50% ethylacetate-hexane) to give unreacted starting material and product as a mixture of diastereomers. The recovered starting material was resubjected to the conditions of the hydrolysis for an additional three days and then worked up as before.
  • the slurry was mixed well with a spatula and allowed to stand with occasional stirring until a uniform, free-flowing powder was obtained. This was then suspended in CFCl 3 (450 mL) at -70° C. and a mixture of fluorine in nitrogen (20%) was introduced slowly through a fritted glass inlet. After 30 minutes, addition of an aliquot to acidic aqueous KI indicated an oxidizing solution. After the addition of the lithium enolate, the solution was stirred for 5 minutes in the cold and then quenched with 400 mL of 5% sodium thiosulfate solution. The aqueous phase was separated and the organic phase was washed further with NaHCO 3 solution and then water.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
US06/932,553 1986-11-20 1986-11-20 12-Halogenated forskolin derivatives Expired - Fee Related US4871764A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US06/932,553 US4871764A (en) 1986-11-20 1986-11-20 12-Halogenated forskolin derivatives
EP87116919A EP0268256A3 (en) 1986-11-20 1987-11-17 12-halogenated forskolin derivatives, intermediates and a process for the preparation thereof and their use as medicaments
PT86176A PT86176B (pt) 1986-11-20 1987-11-19 Processo para a preparacao de derivados de forscolina 12-halogenados
KR870013004A KR880006223A (ko) 1986-11-20 1987-11-19 12- 할로겐화 포스콜린 유도체, 중간체 및 이의 제조방법, 및 약제로서의 이의 용도
JP62290788A JPS63135379A (ja) 1986-11-20 1987-11-19 １２−ハロゲン化ホルスコリン誘導体
DK607787A DK607787A (da) 1986-11-20 1987-11-19 12-halogenerede forskolin-derivater, deres fremstilling og anvendelse
IE873119A IE873119L (en) 1986-11-20 1987-11-19 12-halogenated forskolin derivatives, intermediates and a¹process for the preparation thereof and their use as¹medicaments
ZA878659A ZA878659B (en) 1986-11-20 1987-11-19 12-halogenated forskolin derivatives,intermediates and a process for the preparation thereof and their use as medicaments
HU875134A HU203886B (en) 1986-11-20 1987-11-19 Process for producing 12-halogeno-forscholine derivatives and pharmaceutical compositions contining them as active components
US07/390,126 US4978678A (en) 1986-11-20 1989-08-07 12-halogenated forskolin derivatives
US07/522,754 US5023344A (en) 1986-11-20 1990-05-14 12-halogenated forskolin derivatives
US07/673,449 US5070209A (en) 1986-11-20 1991-04-12 12-halogenated forskolin derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/932,553 US4871764A (en) 1986-11-20 1986-11-20 12-Halogenated forskolin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US07/390,126 Division US4978678A (en) 1986-11-20 1989-08-07 12-halogenated forskolin derivatives

Publications (1)

Publication Number Publication Date
US4871764A true US4871764A (en) 1989-10-03

Family

ID=25462489

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/932,553 Expired - Fee Related US4871764A (en) 1986-11-20 1986-11-20 12-Halogenated forskolin derivatives

Country Status (9)

Country Link
US (1) US4871764A (da)
EP (1) EP0268256A3 (da)
JP (1) JPS63135379A (da)
KR (1) KR880006223A (da)
DK (1) DK607787A (da)
HU (1) HU203886B (da)
IE (1) IE873119L (da)
PT (1) PT86176B (da)
ZA (1) ZA878659B (da)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978678A (en) * 1986-11-20 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 12-halogenated forskolin derivatives
US5371104A (en) * 1989-03-08 1994-12-06 Feigenbaum; Jeffery J. Compositions containing forskolin
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591196B2 (en) * 1985-11-15 1989-11-30 Nippon Kayaku Kabushiki Kaisha Novel forskolin derivatives
US5093336A (en) * 1989-07-06 1992-03-03 Hoechat-Roussel Pharmaceuticals, Inc. 6- and 7-deoxyforskolin and derivatives thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134986A (en) * 1976-12-03 1979-01-16 Hoechst Aktiengesellschaft Polyoxygenated labdane derivatives
DE3346869A1 (de) * 1982-12-27 1984-07-12 Schering Corp., Kenilworth, N.J. Neue labdan-derivate, verfahren zu ihrer herstellung und labdan-derivate enthaltende pharmazeutische zusammensetzungen
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma
US4639443A (en) * 1985-03-01 1987-01-27 Hoechst-Roussel Pharmaceuticals Inc. Labdane compounds, pharmaceutical compositions and use
US4639446A (en) * 1984-12-14 1987-01-27 Hoechst-Roussel Pharmaceuticals Inc. Aminoacyllabdanes, pharmaceutical compositions and use
US4677103A (en) * 1985-03-01 1987-06-30 Hoechst-Roussel Pharmaceuticals Inc. Labdane compounds, pharmaceutical compositions and use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134986A (en) * 1976-12-03 1979-01-16 Hoechst Aktiengesellschaft Polyoxygenated labdane derivatives
DE3346869A1 (de) * 1982-12-27 1984-07-12 Schering Corp., Kenilworth, N.J. Neue labdan-derivate, verfahren zu ihrer herstellung und labdan-derivate enthaltende pharmazeutische zusammensetzungen
US4517200A (en) * 1982-12-27 1985-05-14 Schering-Plough Corporation Method for treating allergic reactions with forskolin
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma
US4639446A (en) * 1984-12-14 1987-01-27 Hoechst-Roussel Pharmaceuticals Inc. Aminoacyllabdanes, pharmaceutical compositions and use
US4639443A (en) * 1985-03-01 1987-01-27 Hoechst-Roussel Pharmaceuticals Inc. Labdane compounds, pharmaceutical compositions and use
US4677103A (en) * 1985-03-01 1987-06-30 Hoechst-Roussel Pharmaceuticals Inc. Labdane compounds, pharmaceutical compositions and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caprioli et al., Forskolio Lowers Intraocular Pressure by Reducing Aqueous Inflow in Invest. Ophthalmol. Vis. Sci., 25, 268, (1984). *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978678A (en) * 1986-11-20 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 12-halogenated forskolin derivatives
US5371104A (en) * 1989-03-08 1994-12-06 Feigenbaum; Jeffery J. Compositions containing forskolin
US5457123A (en) * 1989-03-08 1995-10-10 Feigenbaum; Jeffery J. Compositions containing forskolin and non-ionic surfactant
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3492106A1 (en) 2013-08-09 2019-06-05 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3884935A1 (en) 2013-08-09 2021-09-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
EP4706758A2 (en) 2019-05-21 2026-03-11 Ardelyx, Inc. Methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
ZA878659B (en) 1988-08-31
DK607787A (da) 1988-05-21
DK607787D0 (da) 1987-11-19
PT86176B (pt) 1990-11-07
EP0268256A3 (en) 1988-08-31
HU203886B (en) 1991-10-28
JPS63135379A (ja) 1988-06-07
PT86176A (en) 1987-12-01
KR880006223A (ko) 1988-07-22
IE873119L (en) 1988-05-20
EP0268256A2 (en) 1988-05-25
HUT47558A (en) 1989-03-28

Similar Documents

Publication Publication Date Title
US4639443A (en) Labdane compounds, pharmaceutical compositions and use
EP0193132B1 (en) Labdan-derivatives, a process for their preparation and their use as medicaments
US4822804A (en) 5,6,7,-trinor-4,8-inter-m-phenylene 2-nor PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them
US5109021A (en) Prostaglandin analogues, process for their preparation and pharmaceutical compositions containing them
US4639446A (en) Aminoacyllabdanes, pharmaceutical compositions and use
US4677103A (en) Labdane compounds, pharmaceutical compositions and use
US4871764A (en) 12-Halogenated forskolin derivatives
EP0191166A2 (en) Aminoacyllabdanes, a process and intermediates for their preparation and their use as medicaments
US4978678A (en) 12-halogenated forskolin derivatives
HU193708B (en) Process for preparing the furyl derivatives of 16-substituted prostaglandines
US5070209A (en) 12-halogenated forskolin derivatives
US4666904A (en) Aminoacyllabdanes, pharmacuetical compositions and use
US5023344A (en) 12-halogenated forskolin derivatives
US4673752A (en) Aminoacyllabdanes
US4424376A (en) Prostacyclin intermediates
US4771049A (en) Labdanes, pharmaceutical compositions and use
US4672115A (en) Process for preparing aminoacyllabdanes
US4883885A (en) Oxolabdanes
US5106996A (en) Process for the preparation of podophyllotoxin
US5763451A (en) Dynemicin analogs
US4963537A (en) Labdane compounds, pharmaceutical compositions and use
EP0279948A1 (en) Novel carbamoyloxylabdanes, intermediates and a process for the preparation thereof and their use as medicaments
US4851397A (en) Labdanes, pharmaceutical compositions, and their use
US4423068A (en) (3.2.0) Bicycloheptanone oxime ethers with therapeutic properties
US4211706A (en) 9-Deoxy-9α,6-nitrilo or 6,9α-imino-17,18-didehydro-PGF compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED, SOME

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SHUTSKE, GREGORY M.;REEL/FRAME:004631/0281

Effective date: 19861114

Owner name: HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED,NEW J

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHUTSKE, GREGORY M.;REEL/FRAME:004631/0281

Effective date: 19861114

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19931003

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362